References

Systemic immunoglobulin light chain amyloidosis

10.1038/s41572-018-0034-3 · 2018 · External reference

Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis

10.1200/jco.2013.50.0892 · 2014 · External reference

Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis

10.1080/13506129.2020.1798224 · 2021 · External reference

Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study

10.1038/s41408-021-00529-w · 2021 · External reference

Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death

10.1182/blood-2016-11-751628 · 2017 · External reference

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

10.1182/blood-2011-10-388462 · 2012 · External reference

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

10.1182/blood-2011-11-390930 · 2012 · External reference

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

10.1182/blood.2019000834 · 2019 · External reference

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

10.1182/blood-2015-01-620302 · 2015 · External reference

Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis

10.1200/jco.20.01285 · 2020 · External reference

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

10.1080/19420862.2015.1007813 · 2015 · External reference

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors

10.4049/jimmunol.1003032 · 2011 · External reference

First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis

10.1182/blood-2016-06-722496 · 2016 · External reference

Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis

10.1182/blood-2017-01-763599 · 2017 · External reference

Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis

10.1038/s41375-018-0262-2 · 2019 · External reference

Daratumumab-based treatment for immunoglobulin light-chain amyloidosis

10.1056/nejmoa2028631 · 2021 · External reference

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

10.1200/jco.2011.37.7614 · 2012 · External reference

Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis

10.1080/13506129.2020.1868810 · 2021 · External reference

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis

10.1182/blood-2017-02-767475 · 2017 · External reference

Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome

10.1182/blood-2017-02-767467 · 2017 · External reference

Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis

10.1080/13506129.2018.1490261 · 2018 · External reference

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains

10.1038/leu.2017.286 · 2018 · External reference

Graded cardiac response criteria for patients with systemic light chain amyloidosis

10.1200/jco.22.00643 · 2023 · External reference

Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosis

10.1001/jamaoncol.2024.2629 · 2024 · External reference

A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis

10.1182/blood-2014-04-570010 · 2014 · External reference

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

10.1038/leu.2012.100 · 2012 · External reference

10.1182/blood-2024-205077

10.1182/blood-2024-205077 · 2024 · External reference

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio

10.1038/s41375-018-0258-y · 2019 · External reference

Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy

10.1038/s41408-020-00355-6 · 2020 · External reference

High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma

10.1038/bcj.2017.75 · 2017 · External reference

Outcomes by cardiac stage in patients with newly diagnosed AL amyloidosis: phase 3 ANDROMEDA trial

10.1016/j.jaccao.2022.08.011 · 2022 · External reference

Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival

2024 · External reference

First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy

10.1111/bjh.18733 · 2023 · External reference

Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study

10.3324/haematol.2024.285145 · 2024 · External reference

Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3B light chain amyloidosis: a phase 2 study by the European Myeloma Network

10.1182/blood-2024-202932 · 2024 · External reference

Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma

10.1056/nejmoa2312054 · 2024 · External reference

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

10.1182/bloodadvances.2019000147 · 2019 · External reference

Systemic amyloidosis

10.1016/s0140-6736(15)01274-x · 2016 · External reference

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score

10.4065/mcp.2010.0480 · 2011 · External reference

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

10.1038/s41408-018-0141-0 · 2018 · External reference